CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK
R Minaa, B Dhakalb, J San-Miguelc, N Lendvaid, M Vogele, K Lif, D Cheng, N Patelh, H Einselei, J Martinez-Lopezj
a University of Torino, Turin, Italy
b Medical College of Wisconsin, Milwaukee, United States
c Cancer Center Clínica Universidad Navarra, Pamplona, Spain
d Janssen Research & Development, Raritan, United States
e Janssen Research & Development, Neuss, Germany
f Janssen Research & Development, Spring House, United States
g Janssen Research & Development, Shanghai, China
h Legend Biotech USA Inc, Somerset, United States
i Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
j Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid, Spain
Ver másLido
457
Vezesque se leu este artigo
137
Total PDF
320
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 23 | 10 | 33 |
| 2025 5 | 35 | 10 | 45 |
| 2025 4 | 34 | 9 | 43 |
| 2025 3 | 56 | 10 | 66 |
| 2025 2 | 31 | 13 | 44 |
| 2025 1 | 39 | 15 | 54 |
| 2024 12 | 36 | 17 | 53 |
| 2024 11 | 43 | 34 | 77 |
| 2024 10 | 23 | 19 | 42 |
